FTSE 100 Live: UK Stocks Poised to Hold Near Record

GSK projects its 2025 results to hit the top end of guidance, forecasting core operating profit and EPS growth at the high end of its 6-8% target ranges. This optimistic outlook, following Q2 results ahead of analyst estimates, is primarily driven by robust performance in its specialty medicines division and ongoing R&D progress, with CEO Emma Walmsley noting double-digit sales growth across key therapeutic areas including Respiratory, Immunology & Inflammation, Oncology, and HIV.

Analysis

GSK has issued a significant upward revision to its 2025 outlook, signaling that full-year results are expected to materialize at the top end of its guidance. This implies core operating profit and earnings per share (EPS) growth will be at the upper limit of the 6% to 8% target range, a clear indication of strong operational momentum and management confidence. The optimistic forecast is substantiated by a second-quarter performance that surpassed analyst estimates. The primary driver for this outperformance is the Specialty Medicines division, which the CEO confirmed is experiencing double-digit sales growth across key therapeutic areas, including Respiratory, Immunology & Inflammation, Oncology, and HIV. This broad-based strength, coupled with stated progress in the R&D pipeline, suggests a robust fundamental picture for the company.

Key Decisions for Investors

• Given the upgraded 2025 guidance and a Q2 earnings beat, investors should re-evaluate their models to reflect growth at the high end of the 6-8% range, which may justify a more bullish stance on the stock.
• Monitor the quarterly sales figures from the Specialty Medicines division, as its continued double-digit growth in Oncology, HIV, and other key areas is critical to sustaining the company's positive trajectory.
• Pay close attention to upcoming announcements related to the R&D pipeline, as any positive developments could serve as further catalysts for share price appreciation.